Advertisement

Clinical Drug Investigation

, Volume 39, Issue 1, pp 27–43 | Cite as

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

  • Zhihang Tao
  • Stanley Xiangyu Li
  • Kai Shen
  • Yunuo Zhao
  • Hao Zeng
  • Xuelei MaEmail author
Systematic Review

Abstract

Background

Neratinib is a novel pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor that has shown promising activity against several types of malignancies, especially HER2-overexpressing breast cancer.

Objective

The objective of the current study was to provide a comprehensive insight into the efficacy and safety profiles of neratinib-based therapies.

Methods

Comprehensive literature searches of the PubMed, EMBASE, and Web of Science electronic databases were performed for all relevant clinical trials. Adverse events (AEs) of any grade and of grade 3 or higher were summarized and event rates were calculated. For controlled trials, odds ratios (ORs) were calculated to determine the role of neratinib in AEs. A random-effects model was applied if heterogeneity was observed (I2 ≥ 50%), otherwise a fixed-effects model was used. Kaplan–Meier survival curves were extracted for hazard ratio (HR) calculation, and survival outcomes were measured by progression-free survival (PFS) and overall survival (OS).

Results

Twenty-three studies and 4896 patients were included in the analysis. The most frequently occurring all-grade AEs in neratinib monotherapy were diarrhea (83.9%), nausea (37.9%), and abdominal pain (28.4%). The most common AEs for grades 3 or 4 were diarrhea (25.1%), dyspnea (5.6%), and abnormalities in liver enzyme levels (4.2%). Diarrhea, the most common AE, can be mitigated by prophylactic loperamide. Neratinib demonstrated promising clinical activity as monotherapy in HER2-positive breast cancer; however, in contrast, the effect became much less significant among HER2-mutated breast cancer patients. Notably, neratinib-based combination therapy achieved a higher response rate than neratinib monotherapy.

Conclusions

Neratinib-based therapies led to a higher frequency of some AEs, although these were mostly tolerable. Most studies demonstrated that neratinib provides a benefit in survival outcome. When combined with other anticancer agents, neratinib may hold promise for treating breast cancer with central nervous system metastases.

Notes

Compliance with Ethical Standards

Funding

There was no funding associated with the completion of this work.

Conflict of interest

Zhihang Tao, Stanley Xiangyu Li, Kai Shen, Yunuo Zhao, Hao Zeng, and Xuelei Ma declare that they have no conflicts of interest.

Supplementary material

40261_2018_719_MOESM1_ESM.pdf (8 mb)
Supplementary material 1 (PDF 8230 kb)

References

  1. 1.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefGoogle Scholar
  2. 2.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRefGoogle Scholar
  3. 3.
    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.CrossRefGoogle Scholar
  4. 4.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.CrossRefGoogle Scholar
  5. 5.
    Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem. 2009;9(3):348–55.CrossRefGoogle Scholar
  6. 6.
    Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11(9):793–800.CrossRefGoogle Scholar
  7. 7.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefGoogle Scholar
  8. 8.
    Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.CrossRefGoogle Scholar
  9. 9.
    Gujral DM, Lloyd G, Bhattacharyya S. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction and heart failure during anthracycline chemotherapy ± trastuzumab. Breast. 2018;37:64–71.CrossRefGoogle Scholar
  10. 10.
    Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–65.CrossRefGoogle Scholar
  11. 11.
    Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15(7):2552–8.CrossRefGoogle Scholar
  12. 12.
    Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301–7.CrossRefGoogle Scholar
  13. 13.
    Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592–605.CrossRefGoogle Scholar
  14. 14.
    Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24(1):109–16.CrossRefGoogle Scholar
  15. 15.
    Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013;108(10):1985–93.CrossRefGoogle Scholar
  16. 16.
    Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013;72(6):1205–12.CrossRefGoogle Scholar
  17. 17.
    Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2 + advanced breast cancer. Eur J Cancer. 2013;49(18):3763–72.CrossRefGoogle Scholar
  18. 18.
    Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the nefert-t randomized clinical trial. JAMA Oncol. 2016;2(12):1557–64.CrossRefGoogle Scholar
  19. 19.
    Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32(32):3626–33.CrossRefGoogle Scholar
  20. 20.
    Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–700.CrossRefGoogle Scholar
  21. 21.
    Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(18):3076–83.CrossRefGoogle Scholar
  22. 22.
    Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945–52.CrossRefGoogle Scholar
  23. 23.
    Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res. 2017;23(19):5687–95.CrossRefGoogle Scholar
  24. 24.
    Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32(2):68–75.CrossRefGoogle Scholar
  25. 25.
    Abbas R, Hug BA, Leister C, Sonnichsen D. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol. 2012;70(1):191–9.CrossRefGoogle Scholar
  26. 26.
    Ito Y, Suenaga M, Hatake K, Takahashi S, Yokoyama M, Onozawa Y, et al. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a phase 1 dose-escalation study. Jpn J Clin Oncol. 2012;42(4):278–86.CrossRefGoogle Scholar
  27. 27.
    Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, et al. Adaptive randomization of Neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.CrossRefGoogle Scholar
  28. 28.
    Swaby R, Blackwell K, Jiang Z, Sun Y, Dieras V, Zaman K, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol. 2009;27(15S):1004.Google Scholar
  29. 29.
    Gajria D, King T, Pannu H, Sakr R, Seidman AD, Modi S, et al. Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: a phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Cancer Res. 2011;71(24 Suppl). http://cancerres.aacrjournals.org/content/71/24_Supplement/PD09-08.
  30. 30.
    Freedman RA, Gelman RS, Melisko ME, Anders CK, Moy B, Blackwell KL, et al. TBCRC 022: phase II trial of neratinib + capecitabine for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer brain metastases. J Clin Oncol. 2017;35(15 Suppl):1005.CrossRefGoogle Scholar
  31. 31.
    Barcenas C, Olek E, Hunt D, Tripathy D, Ibrahim E, Wilkinson M et al. Incidence and severity of diarrhea with neratinib plus intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): interim analysis from the multicenter, open-label, phase II control trial. Cancer Res. 2017;77(4 Suppl).Google Scholar
  32. 32.
    Gandhi L, Besse B, Mazieres J, Waciar S, Cortot A, Barlesi F, et al. Neratinib ± temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study. J Thorac Oncol. 2017;12(1):S358–9.CrossRefGoogle Scholar
  33. 33.
    Hyman D, Piha-Paul S, Saura C, Arteaga C, Mayer I, Shapiro G, et al. Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): preliminary analysis from the phase II SUMMIT trial. Cancer Res. 2017;77(4 Suppl).Google Scholar
  34. 34.
    Onozawa Y, Watanabe J, Yamamoto N, Boku N, Suzuki M, Takenake N et al. A Phase 1 Study of Neratinib in combination with Vinorelbine in Japanese patients with advanced or metastatic solid tumours. European Journal of Cancer. 2011;47:S350-S.Google Scholar
  35. 35.
    Wiseman LR, Spencer CM. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging. 1998;12(4):305–34.CrossRefGoogle Scholar
  36. 36.
    Opleta-Madsen K, Hardin J, Gall DG. Epidermal growth factor upregulates intestinal electrolyte and nutrient transport. Am J Physiol. 1991;260(6 Pt 1):G807–14.Google Scholar
  37. 37.
    Goodlad RA, Raja KB, Peters TJ, Wright NA. Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity. Gut. 1991;32(9):994–8.CrossRefGoogle Scholar
  38. 38.
    Ustaris F, Saura C, Di Palma J, Bryce R, Moran S, Neuman L, et al. Effective management and prevention of Neratinib-induced diarrhea. Am J Hematol Oncol. 2015;11(11):13–22.Google Scholar
  39. 39.
    Dirican A, Levent F, Alacacioglu A, Kucukzeybek Y, Varol U, Kocabas U, et al. Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress. Angiology. 2014;65(10):944–9.CrossRefGoogle Scholar
  40. 40.
    Hug B, Abbas R, Leister C, Burns J, Sonnichsen D. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res. 2010;16(15):4016–23.CrossRefGoogle Scholar
  41. 41.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30.CrossRefGoogle Scholar
  42. 42.
    Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259–70.CrossRefGoogle Scholar
  43. 43.
    O’Donovan N, Byrne AT, O’Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investig New Drugs. 2011;29(5):752–9.CrossRefGoogle Scholar
  44. 44.
    Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608–17.CrossRefGoogle Scholar
  45. 45.
    Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9):1837–46.CrossRefGoogle Scholar
  46. 46.
    Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015;16(16):1700–10.CrossRefGoogle Scholar
  47. 47.
    O’Sullivan CC, Davarpanah NN, Abraham J, Bates SE. Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017;44(2):85–100.CrossRefGoogle Scholar
  48. 48.
    Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.CrossRefGoogle Scholar
  49. 49.
    Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011;13(6):R121.CrossRefGoogle Scholar
  50. 50.
    Scaltriti M, Carmona FJ, Toska E, Cocco E, Hyman D, Cutler R, et al. Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy. Eur J Cancer. 2016;69:S125.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  2. 2.West China School of Medicine, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  3. 3.Schulich School of Medicine and DentistryWestern UniversityLondonCanada

Personalised recommendations